Back to the future: Introducing theJournal of Medical Toxicology

Por Osterhoudt, Kevin C., Burkhart, Keith
Publicado em 2005

Data Mining FAERS to Analyze Molecular Targets of Drugs Highly Associated with Stevens-Johnson Syndrome

Por Burkhart, Keith K., Abernethy, Darrell, Jackson, David
Publicado no J Med Toxicol (2015)

Association Between Serotonin Syndrome and Second‐Generation Antipsychotics via Pharmacological Target‐Adverse Event Analysis

Por Racz, Rebecca, Soldatos, Theodoros G., Jackson, David, Burkhart, Keith
Publicado no Clin Transl Sci (2018)

Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science

Por Rouse, Rodney, Kruhlak, Naomi, Weaver, James, Burkhart, Keith, Patel, Vikram, Strauss, David G.
Publicado no Ther Innov Regul Sci (2017)

Linking MedDRA®-coded Clinical Phenotypes to Biological Mechanisms by The Ontology of Adverse Events: A pilot study on Tyrosine Kinase Inhibitors (TKIs)

Por Sarntivijai, Sirarat, Zhang, Shelley, Jagannathan, Desikan G., Zaman, Shadia, Burkhart, Keith K., Omenn, Gilbert S., He, Yongqun, Athey, Brian D., Abernethy, Darrell R.
Publicado no Drug Saf (2016)

Plasma and Urine Dimercaptopropanesulfonate Concentrations after Dermal Application of Transdermal DMPS (TD-DMPS)

Por Cohen, Jennifer P., Ruha, Anne-Michelle, Curry, Steven C., Biswas, Kallol, Westenberger, Benjamin, Ye, Wei, Caldwell, Kathleen L., LoVecchio, Frank, Burkhart, Keith, Samia, Nasr
Publicado em 2012

Safety and Efficacy of Flumazenil for Reversal of Iatrogenic Benzodiazepine-Associated Delirium Toxicity During Treatment of Alcohol Withdrawal, a Retrospective Review at One Cente...

Por Moore, Philip W., Donovan, J Ward, Burkhart, Keith K., Waskin, Jeffrey A., Hieger, Michelle A., Adkins, Audrey R., Wert, Yijin, Haggerty, David A., Rasimas, J. J.
Publicado em 2014